ArticleMolecular genetics and metabolism reports2026
Quality of life after diet liberalization in individuals with phenylketonuria treated with Pegvaliase.
Article in Molecular genetics and metabolism reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the impact of pegvaliase treatment on quality of life and individuals' perception of and satisfaction with therapy in Italian individuals with classical phenylketonuria (PKU) after diet liberalization. Methods: This longitudinal observational study included individuals with classical PKU and persistently poor dietary adherence who initiated treatment with pegvaliase and achieved diet liberalization. Blood Phe levels were measured at baseline and throughout treatment for up to 12 months following diet liberalization. Quality of life was assessed using the Phenylketonuria-Quality of Life (PKU-QOL) questionnaire at three time points (before treatment, and 6 and 12 months after diet liberalization); a qualitative satisfaction survey was also administered. Results: Seven participants (1 male, 6 females; mean age 27.7 years) achieved diet liberalization within a mean of 61 weeks after maintenance period, with a mean reduction in blood Phe levels of 79.7%. At 6 and 12 months after diet liberalization, PKU-QOL scores showed a consistent decrease, indicating improved quality of life, particularly in the "PKU in general" subscale, assessing the emotional, practical, and social impact of PKU. Patient-reported outcomes highlighted improvements in energy levels, sleep quality, emotional well-being, and social functioning. Common challenges included injection-site discomfort and initial treatment-related anxiety. Conclusions: Pegvaliase treatment was effective in reducing blood Phe levels and achieving diet liberalization, thereby improving quality of life in individuals with PKU who historically had poor dietary adherence. Despite initial treatment challenges, the therapy enabled substantial improvements in quality of life and dietary freedom.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.